The publication of the trial design by a reputable organization like the European Society of Cardiology Heart Failure is a positive development for Windtree Therapeutics. It indicates progress in their clinical trials, which could lead to future advancements and potential market approval. This news is likely to boost investor confidence and positively impact the stock price in the short term.